Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA.

Abstract:

:The RNA N-glycosidase ribosome inactivating proteins (RIPs) constitute a ubiquitous family of plant- and bacterium-derived toxins that includes the category B select agents ricin, abrin and shiga toxin. While these toxins are potent inducers of intestinal epithelial cell death and inflammation, very little is known about the mechanisms underlying mucosal immunity to these toxins. In the present study, we report that secretory IgA (SIgA) antibodies are not required for intestinal immunity to ricin, as evidenced by the fact that mice devoid of SIgA, due to a mutation in the polymeric immunoglobulin receptor, were impervious to the effects of intragastric toxin challenge following ricin toxoid immunization. Furthermore, parenteral administration of ricin-specific monoclonal IgGs, directed against either ricin's enzymatic subunit (RTA) or ricin's binding subunit (RTB), to wild type mice was as effective as monoclonal IgAs with comparable specificities in imparting intestinal immunity to ricin. These data are consistent with reports from others demonstrating that immunization of mice by routes known not to induce mucosal antibody responses (e.g., intramuscular and intradermal) is sufficient to elicit protection against both systemic and mucosal ricin challenges.

journal_name

Vaccine

journal_title

Vaccine

authors

Neal LM,McCarthy EA,Morris CR,Mantis NJ

doi

10.1016/j.vaccine.2010.11.030

subject

Has Abstract

pub_date

2011-01-17 00:00:00

pages

681-9

issue

4

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(10)01639-7

journal_volume

29

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Influenza vaccination in 22 developed countries: an update to 1995.

    abstract::This study expands and updates through 1995 our earlier report on influenza vaccine use in 18 developed countries. Five of the six countries with high levels of vaccine use in 1992 (> or = 130 doses/1000 population) showed little change or slight declines over the subsequent 3 years. The exception was the United State...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00091-1

    authors: Fedson DS,Hirota Y,Shin HK,Cambillard PE,Kiely J,Ambrosch F,Hannoun C,Leese J,Sprenger MJ,Hampson AW,Bro-Jørgensen K,Ahlbom AM,Nøkleby H,Valle M,Olafsson O,Salmerón F,Cloetta J,Rebelo de Andrade H,Snacken R,Donatell

    更新日期:1997-10-01 00:00:00

  • Retro-inversion enhances the adjuvant and CpG co-adjuvant activity of host defence peptide Bac2A.

    abstract::Host defence peptides (HDPs) have a variety of potential therapeutic applications, including as vaccine adjuvants, energizing efforts for modification strategies to address their toxicity and instability. Here we compare l, d and RI-Bac2A as vaccine adjuvants. d and RI-Bac2A are equally resistant to proteolytic degrad...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.02.015

    authors: Scruten E,Kovacs-Nolan J,Griebel PJ,Latimer L,Kindrachuk J,Potter A,Babiuk LA,Littel-van den Hurk Sv,Napper S

    更新日期:2010-04-09 00:00:00

  • The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice.

    abstract::We have previously described the generation of HIV-1 V3-specific cytotoxic T-lymphocytes (CTL) responses in BALB/c (H-2d) mice following immunization with Ty-virus-like particles carrying the V3 loop of gp120 (V3-VLPs) without adjuvant. In this study the effects of various adjuvants on CTL induction by V3-VLPs was exa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(96)00010-2

    authors: Harris SJ,Woodrow SA,Gearing AJ,Adams SE,Kingsman AJ,Layton GT

    更新日期:1996-07-01 00:00:00

  • Complement and antibodies: a dangerous liaison in HIV infection?

    abstract::Due to ongoing recombination and mutations, HIV permanently escapes from neutralizing antibody (nAb) responses of the host. By the masking of epitopes or shedding of gp120, HIV-1 further impedes an efficient neutralization by Abs. Therefore, nAbs responses of the host are chasing behind a rapidly evolving virus and ma...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2008.11.050

    authors: Stoiber H,Soederholm A,Wilflingseder D,Gusenbauer S,Hildgartner A,Dierich MP

    更新日期:2008-12-30 00:00:00

  • Implementation of good clinical practice guidelines in vaccine trials in developing countries.

    abstract::The practicalities when applying the ICH GCPs (International Conference on Harmonization 1996 Good Clinical Practices [EU, MHLW, FDA. International Conference on Harmonization Guideline for Good Clinical Practice; 1997] in less developed countries (ldcs) are seldom discussed and we found no guidelines as how to "adapt...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.079

    authors: Acosta CJ,Galindo CM,Ochiai RL,Danovaro-Holliday MC,Laure-Page A,Thiem VD,Jin Y,Khan MI,Sahito SM,Hamza HB,Park JK,Lee H,Bock H,Elyazeed RA,Albert MJ,Ascaso C,Robles TQ,Ali M,Ngai P,Puri MK,Koo YM,Agtini MD,So

    更新日期:2007-04-12 00:00:00

  • Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99.

    abstract::In an effort to develop a safe and effective vaccine for the prevention of enterotoxigenic Escherichia coli (ETEC) K99 infections, we have developed a surface antigen display system using pgsA (poly-gamma-glutamate synthetase A) as an anchoring matrix. The recombinant fusion proteins comprised of pgsA and fimbriae pro...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.05.088

    authors: Wei CH,Liu JK,Hou XL,Yu LY,Lee JS,Kim CJ

    更新日期:2010-05-28 00:00:00

  • Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.

    abstract::Pfs25, a Plasmodium falciparum surface protein expressed during zygote and ookinete stages in infected mosquitoes, is a lead transmission-blocking vaccine candidate against falciparum malaria. To enhance immunogenicity, recombinant Pfs25 was chemically conjugated to recombinant nontoxic Pseudomonas aeruginosa ExoProte...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.04.067

    authors: Zhu D,Wu Y,McClellan H,Dai W,Rausch K,Jones D,Aebig J,Barnafo E,Butler B,Lambert L,Narum DL,Duffy PE

    更新日期:2017-05-31 00:00:00

  • Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.

    abstract::The level of protection conferred by foot-and-mouth disease (FMD) vaccines in primovaccinated animals primarily depends on the potency of the vaccine and the relatedness of the vaccine strain and circulating field isolate. The "Gold Standard" FMD vaccine potency test is the in vivo test performed in the target species...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.04.034

    authors: Goris N,Maradei E,D'Aloia R,Fondevila N,Mattion N,Perez A,Smitsaart E,Nauwynck HJ,La Torre J,Palma E,De Clercq K

    更新日期:2008-06-25 00:00:00

  • Hepatitis A shifting epidemiology in Latin America.

    abstract::In the past, Latin America was considered to be an area of high endemicity for hepatitis A virus (HAV) infection, with most people infected in early childhood. A seroepidemiological study was recently undertaken in six countries to determine whether this pattern has changed. The highest seroprevalence of antibodies to...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00466-1

    authors: Tanaka J

    更新日期:2000-02-18 00:00:00

  • Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.

    abstract::A trial of the ALVAC-AIDSVAX HIV vaccine was recently found to be partially effective in preventing HIV transmission among study participants in Thailand. The success of this trial means that vaccination may become a viable intervention for the prevention of HIV infection in the medium-term future. Assuming that the v...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.06.061

    authors: Gray RT,Ghaus MH,Hoare A,Wilson DP

    更新日期:2011-08-18 00:00:00

  • Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy).

    abstract::The aim of the study was to investigate factors involved in vaccination acceptance among healthcare workers (HCWs) and adverse reactions rates associated with pandemic influenza vaccination. The study was carried out in the major teaching hospital of Sicily from November 2009 to February 2010 on 2267 HCWs. A total of ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.12.041

    authors: Amodio E,Anastasi G,Marsala MG,Torregrossa MV,Romano N,Firenze A

    更新日期:2011-02-04 00:00:00

  • Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.

    abstract::Malaria transmission-blocking vaccines (TBV) targeting sexual stages of the parasite represent an ideal intervention to reduce the burden of the disease and eventual elimination at the population level in endemic regions. Immune responses against sexual stage antigens impair the development of parasite inside the mosq...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.08.025

    authors: Kumar R,Ray PC,Datta D,Bansal GP,Angov E,Kumar N

    更新日期:2015-09-22 00:00:00

  • Evidence of cross-protection within Leptospira interrogans in an experimental model.

    abstract::Killed whole-cell preparations were used as bacterins against leptospirosis. As this type of protection is considered to be serogroup-specific, several serogroups were added to the usual vaccines, and the most pathogenic serovar was chosen for each group. Different leptospire extracts were evaluated for their protecti...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00129-8

    authors: Sonrier C,Branger C,Michel V,Ruvoën-Clouet N,Ganière JP,André-Fontaine G

    更新日期:2000-08-15 00:00:00

  • Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine.

    abstract::In order to evaluate in humans the safety and immunogenicity of a Pseudomonas aeruginosa vaccine composed of outer membrane proteins (OMPs), CFC-101, we carried out a phase I/IIa clinical trial in healthy male volunteers. Groups of six volunteers were immunized either subcutaneously (s.c.) or intramuscularly (i.m.) wi...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0264-410x(98)00159-5

    authors: Jang IJ,Kim IS,Park WJ,Yoo KS,Yim DS,Kim HK,Shin SG,Chang WH,Lee NG,Jung SB,Ahn DH,Cho YJ,Ahn BY,Lee Y,Kim YG,Nam SW,Kim HS

    更新日期:1999-01-01 00:00:00

  • Improved vaccination against Newcastle disease by an in ovo recombinant HVT-ND combined with an adjuvanted live vaccine at day-old.

    abstract::The continuous outbreaks of fatal Newcastle disease (ND) in commercial poultry flocks demonstrate that current vaccination strategies are not fully efficacious and should be improved by new generation of vaccines. In this context, maternally immune conventional layer chickens were vaccinated in ovo with a turkey herpe...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.049

    authors: Rauw F,Gardin Y,Palya V,Anbari S,Lemaire S,Boschmans M,van den Berg T,Lambrecht B

    更新日期:2010-01-08 00:00:00

  • Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.

    abstract::It has been hypothesized that antibody induced by Plasmodium falciparum circumsporozoite protein vaccine would be effective against endemic human malaria. In a malaria endemic region of Kenya, 76 volunteers, in 38 pairs sleeping adjacently, were immunized with subunit circumsporozoite protein Asn-Ala-Asn-Pro tetrapept...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(95)00221-l

    authors: Sherwood JA,Copeland RS,Taylor KA,Abok K,Oloo AJ,Were JB,Strickland GT,Gordon DM,Ballou WR,Bales JD Jr,Wirtz RA,Wittes J,Gross M,Que JU,Cryz SJ,Oster CN,Roberts CR,Sadoff JC

    更新日期:1996-06-01 00:00:00

  • Flagellin enhances the immunoprotection of formalin-inactivated Edwardsiella tarda vaccine in turbot.

    abstract::Edwardsiella tarda is an important fish pathogen that causes extensive losses in farmed fish around the world. Various types of vaccines have been developed against E. tarda infection, such as inactivated vaccine, live attenuated vaccine and subunit vaccine. However, inactivated vaccine exhibits poor immune protection...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.11.031

    authors: Liu X,Zhang H,Jiao C,Liu Q,Zhang Y,Xiao J

    更新日期:2017-01-05 00:00:00

  • Biodistribution and lymph node retention of polysaccharide-based immunostimulating nanocapsules.

    abstract::The adjuvant properties of polyglucosamine/squalene-based nanocapsules (PG-nanocapsules) associated with different subunit antigens has been previously reported. Thus, the aim of the present study was to monitor the biodistribution of PG-nanocapsules and their affinity for the draining lymph nodes after subcutaneous (...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.01.059

    authors: Vicente S,Goins BA,Sanchez A,Alonso MJ,Phillips WT

    更新日期:2014-03-26 00:00:00

  • Bacillus spores for vaccine delivery.

    abstract::Spores of the genus Bacillus have been used for a long time as probiotics for oral bacteriotherapy both in humans and in animals. Spores are also employed in a veterinary vaccine against anthrax. Despite this long lasting and extensive use, the specific contribution of spores to the beneficial effects of probiotics an...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(03)00207-x

    authors: Oggioni MR,Ciabattini A,Cuppone AM,Pozzi G

    更新日期:2003-06-01 00:00:00

  • Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease.

    abstract::The goal of the present study was to evaluate the influence of the influenza A H1N1/2009 vaccine on dermatomyositis/polymyositis (DM/PM) disease parameters and the potential deleterious effect of therapy on immune response. Thirty-seven DM and 21 PM patients (Bohan and Peter's criteria) were gender- and age-matched to...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.10.063

    authors: Shinjo SK,de Moraes JC,Levy-Neto M,Aikawa NE,de Medeiros Ribeiro AC,Schahin Saad CG,Precioso A,Silva CA,Bonfá E

    更新日期:2012-12-17 00:00:00

  • Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis.

    abstract::The bacillus Calmette Guérin (BCG) vaccine, the only licensed vaccine against TB, displays partial and variable efficacy, thus making the exploitation of novel vaccination strategies a major priority. Most of the current vaccines in pre-clinical or clinical development are based on the induction of T cells recognizing...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.01.079

    authors: Larrouy-Maumus G,Layre E,Clark S,Prandi J,Rayner E,Lepore M,de Libero G,Williams A,Puzo G,Gilleron M

    更新日期:2017-03-07 00:00:00

  • Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.

    abstract::Dengue fever is a growing public health concern around the world and despite vaccine development efforts, there are currently no effective dengue vaccines. In the present study we report the induction of protective antibodies against dengue virus by DNA immunization with domain III (DIII) region of the envelope protei...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.12.028

    authors: Mota J,Acosta M,Argotte R,Figueroa R,Méndez A,Ramos C

    更新日期:2005-05-16 00:00:00

  • Burden of rotavirus disease and cost-effectiveness of universal vaccination in the Province of Genoa (Northern Italy).

    abstract::Rotavirus is acknowledged to be a major cause of acute gastroenteritis in infants and young children. As gastroenteritis due to rotavirus is a public health problem and two new vaccines are currently available, we investigated the rotavirus burden and developed a cost-effectiveness analysis, using data collected in th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.054

    authors: Panatto D,Amicizia D,Ansaldi F,Marocco A,Marchetti F,Bamfi F,Giacchino R,Tacchella A,Del Buono S,Gasparini R

    更新日期:2009-05-26 00:00:00

  • Compatibility of a live infectious bovine rhinotraheitis (IBR) marker vaccine and an inactivated bovine viral diarrhoea virus (BVDV) vaccine.

    abstract::The target animals and vaccination regimes for vaccines against the bovine rhinotracheitis (IBR) and the bovine viral diarrhoea virus (BVDV) are very similar. Therefore, we have compared different schedules for the combined use of a live IBR marker vaccine and an inactivated BVD vaccine. The neutralizing antibody resp...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.06.050

    authors: Alvarez M,Bielsa JM,Santos L,Makoschey B

    更新日期:2007-09-04 00:00:00

  • Influenza vaccination among U.S. pediatric patients receiving care from federally funded health centers.

    abstract:INTRODUCTION:During the 2018-2019 influenza season, vaccination coverage among U.S. children was 62.6%. The purpose of this study was to estimate the prevalence of influenza vaccinations among pediatric patients seen in U.S. health centers, and to explore potential disparities in vaccination coverage among subpopulatio...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.07.021

    authors: Lebrun-Harris LA,Mendel Van Alstyne JA,Sripipatana A

    更新日期:2020-09-03 00:00:00

  • ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.

    abstract::ISCOMATRIX adjuvant is capable of inducing broad and potent humoral and cellular immune responses. The components are well defined and the manufacturing process is simple and robust. Many vaccines containing the ISCOMATRIX adjuvant have been tested in a range of animal models, including human and non-human primates. S...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2003.12.031

    authors: Pearse MJ,Drane D

    更新日期:2004-06-23 00:00:00

  • Varicella vaccination coverage in Bavaria (Germany) after general vaccine recommendation in 2004.

    abstract::Since 2004, general varicella vaccination has been recommended for all children 11-14 months of age in Germany. The objective of this study was to examine vaccination coverage in children and factors associated with parental acceptance during the first years after recommendation. In a regional surveillance area, cross...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.06.007

    authors: Streng A,Seeger K,Grote V,Liese JG

    更新日期:2010-08-09 00:00:00

  • Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation.

    abstract:BACKGROUND:Current national immunisation schedules differ between countries in terms of vaccine formulation, timing of vaccinations and immunisation programme funding and co-ordination. As a result, some HIV infected paediatric population may be left susceptible to vaccine preventable infections. Vaccines used in healt...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2016.09.035

    authors: Bamford A,Manno EC,Mellado MJ,Spoulou V,Marques L,Scherpbier HJ,Niehues T,Oldakowska A,Rossi P,Palma P,PENTA-vac Group.

    更新日期:2016-11-04 00:00:00

  • Recombinant flagellins with deletions in domains D1, D2, and D3: Characterization as novel immunoadjuvants.

    abstract::Bacterial flagellin activates the innate immune system and ultimately the adaptive immune system through a Toll-like receptor 5 (TLR5)-dependent signaling mechanism. Given that TLR5 is widely distributed in epithelia, flagellin is currently being developed as a mucosal adjuvant. Flagellin FliC from Salmonella enterica...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.12.009

    authors: Biedma ME,Cayet D,Tabareau J,Rossi AH,Ivičak-Kocjan K,Moreno G,Errea A,Soulard D,Parisi G,Jerala R,Berguer P,Rumbo M,Sirard JC

    更新日期:2019-01-21 00:00:00

  • In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus.

    abstract::The hypervariable region 1 (HVR1) of hepatitis C virus (HCV) may contain neutralizing epitopes. A chimpanzee in whom cross-reactive anti-HVR1 antibodies had been induced by immunization was challenged with heterologous HCV for clarifying whether cross-reactive anti-HVR1 antibodies can neutralize heterologous HCV. Acut...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00271-2

    authors: Esumi M,Zhou YH,Tanoue T,Tomoguri T,Hayasaka I

    更新日期:2002-08-19 00:00:00